Eli Lilly & Co.(NYSE:LLY) shares have nosedived 12.5% month-to-date through Nov. 19, putting the stock on track for its worst monthly performance since February 2009, when it tumbled 20.2%.
The pharmaceutical giant, which ranks 11th by market capitalization in the S&P 500 and holds the top spot among health care stocks, is reeling from a disappointing third-quarter earnings report and lowered guidance.
The sell-off raised doubts about the near-term prospects for Lilly's high-profile drugsMounjaroandZepbound, which missed revenue expectations and contributed to a storm of investor uncertainty.
For traders, the burning question now is whether...
ログインすると全部閲覧できます。
ログイン
